Saluda Medical Evoke SCS System
Saluda Medical Pty, Ltd. · Decision date Oct 15, 2026
What did the FDA decide?
The FDA record lists PMA supplement P190002/S051 for Saluda Medical's Evoke spinal cord stimulation system under a 30-Day Notice. The stated change: "change the formulation of the adhesive used on the Tyvek packaging of the paddle lead kit." The supplement reason is "Process Change - Manufacturer/Sterilizer/Packager/Supplier," and the device category is a totally implanted spinal-cord stimulator for pain relief (product code LGW, Neurology).
Because S051 carries the P190002 number, it is a supplement to that original PMA rather than a separate approval of the system. The record does not identify the prior or new adhesive formulation, the supplier, the sterilization route, or supporting data, and the reported purpose is not independent proof of safety or clinical effectiveness. The database shows decision code OK30 dated 2026-10-15.
FDA approval order statement
change the formulation of the adhesive used on the Tyvek packaging of the paddle lead kit
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190002/S051
- Regulatory pathway
- PMA supplement
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Oct 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190002 · Original PMA
Saluda Medical Evoke SCS System
P190002/S051 received
Application receipt date recorded by FDA.
P190002/S051 · FDA decision
30-Day Notice
P190002/S052 · Related supplement
Saluda Medical Evoke SCS System
Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Saluda Medical Pty, Ltd. | PMA approval | Feb 28, 2022 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Saluda Medical Pty, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Level 1, 407 Pacific Hwy., Atarmon, NSW 2064
Sources and methodology
- Original FDA record: P190002/S051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



